LONDON: Graft Polymer (UK) Plc, a biotechnology company co-developing therapeutics for mental health disorders, announced it has entered a binding letter of agreement to acquire all issued share capital of Awakn Life Sciences Corp., a clinical-stage biotechnology firm focused on treating substance use and mental health disorders. Under the terms of the proposed acquisition, Graft…